Statements (23)
| Predicate | Object |
|---|---|
| gptkbp:instanceOf |
gptkb:drug
histone deacetylase inhibitor |
| gptkbp:administeredBy |
oral
|
| gptkbp:alternativeName |
ricolinostat
|
| gptkbp:CASNumber |
1322046-50-9
|
| gptkbp:clinicalTrialPhase |
Phase 1
Phase 2 |
| gptkbp:criteria |
selective for HDAC6
|
| gptkbp:developedBy |
Acetylon Pharmaceuticals
|
| gptkbp:effect |
induces apoptosis in cancer cells
disrupts aggresome formation |
| gptkbp:hasMolecularFormula |
C21H23N3O3
|
| https://www.w3.org/2000/01/rdf-schema#label |
ACY-1215 (ricolinostat)
|
| gptkbp:investigatedBy |
leukemia
multiple myeloma solid tumors |
| gptkbp:mechanismOfAction |
inhibits histone deacetylase 6
|
| gptkbp:molecularWeight |
365.43 g/mol
|
| gptkbp:PubChem_CID |
CHEMBL2103887
46209416 |
| gptkbp:target |
gptkb:HDAC6
|
| gptkbp:bfsParent |
gptkb:HDAC6
|
| gptkbp:bfsLayer |
7
|